Clik here to view.
Strand Life Sciences Announces Key Publication Demonstrating Clinical Utility...
BANGALORE, India & AURORA, Colo. Strand Life Sciences, a global leader in precision medicine diagnostics, announced the publication of a landmark study in the Journal of Human Genetics in a...
View ArticleClik here to view.
Hutchison China MediTech Limited Announces Launch of Potential U.S. Public...
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares...
View ArticleClik here to view.
Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in...
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the results of global phase II study of anti-IL-31 receptor A, humanized monoclonal antibody, nemolizumab (CIM331), which is...
View ArticleClik here to view.
Crown Bioscience收购PreClinOmics，壮大心血管及代谢疾病产品阵容
加州圣克拉拉 (美国商业资讯) — Crown Bioscience International (TWSE:ticker 6554)是一家全球性药物发现及开发解决方案公司，提供促进肿瘤学和代谢疾病研究的转化平台，其全资子公司Crown Bioscience, Inc.宣布收购PreClinOmics,...
View ArticleClik here to view.
Premier Biomedical, Inc. Engages Agent in India to Identify Suitable Joint...
EL PASO, Texas Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in...
View ArticleClik here to view.
クラウン・バイオサイエンスがPreClinOmicsを買収し、心血管・代謝疾患のポートフォリオを拡大
米カリフォルニア州サンタクララ （ビジネスワイヤ） — 世界的な創薬・医薬品開発ソリューション企業としてオンコロジーと代謝疾患の研究を前進させる橋渡し的プラットフォームを提供するクラウン・バイオサイエンス・インターナショナル（TWSE:ticker 6554）の完全子会社であるクラウン・バイオサイエンスは、PreClinOmics, Inc.の買収を発表しました。PreClinOmicsはin...
View ArticleClik here to view.
豪雅集团任命Gerald W. Bottero为宾得医疗全球总裁
东京 (美国商业资讯) — 豪雅集团下属宾得医疗宣布任命Gerald W. Bottero为宾得医疗全球总裁，自2016年2月1日起生效。 豪雅集团总裁兼首席执行官Hiroshi Suzuki说：“豪雅集团很高兴由Gerald W....
View ArticleClik here to view.
Cantargia AB: Cantargia Receives Patent Approval in Japan and Mexico
STOCKHOLM Cantargia AB (“Cantargia”) has received approval in Japan and Mexico for its patent application covering IL1RAP as a target molecule for antibody therapy and leukemia diagnostics. The...
View ArticleClik here to view.
AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for...
CAMBRIDGE, Mass. & BEIJING AVEO Oncology (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, today...
View ArticleClik here to view.
Chi-Med Initiates Sulfatinib Phase III Registration Study in Pancreatic...
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III...
View ArticleClik here to view.
がん治療法は自分で選べる時代がん免疫細胞療法セミナー、福岡市で開催、参加者を募集：リンパ球バンク株式会社
東京 （ビジネスワイヤ） — がん免疫治療で先進的な取り組みをしている京都大学発のベンチャー企業、リンパ球バンク株式会社（本社：東京都千代田区、代表取締役：藤井真則）は、今、注目を集めているがん免疫治療について広く知っていただくため、読売新聞西部本社後援・市民公開講座「がん免疫細胞療法セミナー」を4月6日（水）福岡市中央区の読売新聞西部本社にて開催します。先着80名様で参加希望者を募集中です。...
View ArticleClik here to view.
Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell...
TOKYO Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) announced today that an Asian Multinational Phase II study of SP-02 (darinaparsin) for...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer...
HYDERABAD, India Dr. Reddy’s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has entered into a licensing agreement with Eisai Co., Ltd, Japan by which Dr. Reddy’s will...
View ArticleClik here to view.
Takeda and Teva Establish “Teva Takeda Yakuhin Ltd.” in Japan
JERUSALEM & OSAKA, Japan Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Takeda Pharmaceutical Company Limited (TSE:4502) announce the establishment of Teva Takeda Yakuhin Ltd....
View ArticleClik here to view.
AntiCancer Inc. and Japanese Scientists Make Beating Heart-Muscle Tissue...
SAN DIEGO AntiCancer Inc. and Japanese scientists from Kitasato University near Tokyo have made beating heart-muscle tissue sheets from hair-follicle-associated pluripotent (HAP) stem cells. HAP...
View ArticleClik here to view.
ノボキュア社と著名ながんセンターが腫瘍治療電場の前臨床研究で提携
ジャージー島セントヘリア （ビジネスワイヤ） — ノボキュア社（NASDAQ: NVCR）は本日、ノボキュア社のinovitro™システムがテキサス大学MDアンダーソンがんセンターにおいて腫瘍治療電場（Tumor Treating...
View ArticleClik here to view.
CANbridge Submits Investigational New Drug Application to Taiwan Food and...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that it has completed the Investigational New Drug (IND)...
View ArticleClik here to view.
Chi-Med Initiates First-in-Human Clinical Trial of Novel PI3K Inhibitor HMPL-689
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”)...
View ArticleClik here to view.
Hutchison China MediTech Limited Announces Exercise of Overallotment Option
LONDON Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the...
View ArticleClik here to view.
Sosei Subsidiary Heptares and Kymab Enter Strategic Collaboration to...
TOKYO Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) today announces Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei, and Kymab Limited, a leading human...
View Article